A novel treatment for healing diabetic foot ulcers (DFUs) could be on the horizon for people with diabetes in the US.
Diabetic foot ulcers are a common and costly complication for people with diabetes. Open sores which are commonly found on the bottom of the foot. DFUs are often a result of peripheral neuropathy, a complication that affects roughly 40% of people with diabetes. DFUs do not heal on their own without medical care, and research has found that around 85% of lower extremity amputations in people with diabetes are preceded by foot ulcers.
However, ON101 cream (brand name Fespixon) is a promising new treatment anticipated for FDA approval in the coming years. Clinical trials have found the wound-healing cream to have significant benefits for DFUs, with study participants experiencing a 60% complete healing rate over 16 weeks, compared to 35% healing with an absorbent wound dressing.
“ON101 cream is an effective treatment to chronic, non-healing DFUs that have failed to heal via conventional therapy,” said Dr. Yur-Ren Kuo, professor and chief of plastic and reconstructive surgery at Kaohsiung Medical University Hospital in Taiwan.
To read more, CLICK HERE.
